Industrial production of a wide range of compounds using genetically engineered microorganisms is a well-established technique. These microbial factories combine the biosynthetic pathways that are employed in the natural sources of the target compounds (e.g. essential oils, flavors and frangrances from plants) and extensively studied low complexity host systems, such as baker’s yeast or the gut bacteria Escherichia coli. Despite the clear advances in production costs and significantly reduced environmental impact, generation of such hybrid microbial factories requires complex genetic engineering process in order to import new biosynthetic pathways into the host system. Recent advances in systems biology and in silico (computational) modelling provide an opportunity to bypass the common trial and error methods that are commonly used in the academia and industry.
Using in silico modelling during the first development stages, EV Biotech optimized the production pipeline, introducing a novel strategy to the market. In contrast with conventional methods, in silico modelling takes into account the entire network of biochemical reactions that occur within the host organism and thus provides the most optimal genetic design for specific compound production. Such method allows maximized production rates while significantly reducing time and costs for development.
This strategy can be applied to a broad industrial range, including Flavours & Fragrances, Pharmaceuticals, Agriculture, Biofuels and Bioplastics. The goal of EV Biotech is to deliver an optimal customer experience, providing tailored design and development of genetically optimized biological systems for target compound production. The aim is superior yield and quality of the desired compound as well as reduced production costs and environmental impact.